About
Contact & Profiles
A5101800864
Research Areas
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Radio Frequency Integrated Circuit Design
Columbia University
2024
Although BRCA1/2 mutations are not commonly found in small cell lung cancer (SCLC), a substantial fraction of SCLC shows clinically relevant response to PARP inhibitors (PARPis). However, the underlying mechanism(s) PARPi sensitivity is poorly understood. We performed quantitative proteomic analyses and identified changes that signify responses cells. vulnerability could be explained by degradation lineage-specific oncoproteins (e.g., ASCL1). PARPi-induced activation E3 ligase HUWE1 mediated...
10.1126/sciadv.adh2579
article
EN
cc-by-nc
Science Advances
2024-01-19
Coming Soon ...